TY - JOUR
T1 - Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
AU - Kantarjian, H. M.
AU - Giles, F. J.
AU - O'Brien, S. M.
AU - Talpaz, M.
PY - 1998
Y1 - 1998
N2 - This article begins with a review of the natural history of chronic myelogenous leukemia (CML), with an emphasis on prognostic features. Current standard therapy of CML with interferon-alpha based regimens, and interferon- alpha, in the context of allogenic stem cell transplantation is then discussed. Finally, some potentially effective novel agents including homoharringtonine, decitabine, ATRA, and topotecan are described.
AB - This article begins with a review of the natural history of chronic myelogenous leukemia (CML), with an emphasis on prognostic features. Current standard therapy of CML with interferon-alpha based regimens, and interferon- alpha, in the context of allogenic stem cell transplantation is then discussed. Finally, some potentially effective novel agents including homoharringtonine, decitabine, ATRA, and topotecan are described.
UR - https://www.scopus.com/pages/publications/0031934179
U2 - 10.1016/S0889-8588(05)70496-2
DO - 10.1016/S0889-8588(05)70496-2
M3 - Article
C2 - 9523225
AN - SCOPUS:0031934179
SN - 0889-8588
VL - 12
SP - 31
EP - 80
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -
